Transcriptomics

Dataset Information

0

Identification of resistance mechanisms to anti-HER2 antibody in breast cancer cell line BT-474


ABSTRACT: Background: The addition of the anti-HER2 antibody pertuzumab to trastuzumab/chemotherapy treatment in HER2+ breast cancer significantly improves clinical outcome. Concomitantly, the drug-antibody conjugate T-DM1 (trastuzumab-emantasine) has demonstrated efficacy, at least equal, to the combination of trastuzumab/chemotherapy. Scientific, economic and health challenges emerge from the clinical use of these novel anti-HER2 antibodies, aimed to identify new resistance mechanisms and to select the target breast cancer population. Objectives: (1) To identify primary resistance mechanisms to anti-HER2 antibodies trastuzumab, pertuzumab, and to the combined trastuzumab/pertuzumab or pertuzumab/T-DM1 therapy, (2) To identify acquired resistance mechanisms to anti-HER2 antibodies trastuzumab, pertuzumab, and to the combined trastuzumab/pertuzumab or pertuzumab/T-DM1 therapy, (3) To develop new combinations of anti-HER2 antibodies with other targeted therapies.

ORGANISM(S): Homo sapiens

PROVIDER: GSE89216 | GEO | 2019/12/31

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2021-08-24 | GSE181574 | GEO
2021-04-09 | PXD021865 | Pride
2024-01-26 | PXD045804 | Pride
2020-11-18 | GSE161743 | GEO
2015-11-09 | E-GEOD-69042 | biostudies-arrayexpress
2015-11-09 | GSE69042 | GEO
2012-05-02 | E-GEOD-31432 | biostudies-arrayexpress
2017-11-28 | GSE107385 | GEO
2022-11-04 | GSE122426 | GEO
2024-02-29 | GSE243375 | GEO